HIV / AIDS in the News

Gilead plans to halt free access to an HIV drug, worrying patient advocates - STAT

 

Positive Destinations: HIV Justice Network Rebrands HIV-Specific Travel Guide - POZ

 

Opinion: The world has a new HIV prevention drug. Let’s use it - Devex

 

Gilead’s twice-yearly PrEP chosen as breakthrough of the year - Bay Area Reporter, America's highest circulation LGBT newspaper

 

Merck's Investigational Two-Drug Regime For HIV Meets Primary Goal In Two Late-Stage Trials - Yahoo Finance

 

Merck's Investigational Two-Drug Regime For HIV Meets Primary Goal In Two Late-Stage Trials - Benzinga

 

Addressing Clinician-Reported Barriers Improves Confidence in PrEP Prescribing - Physician's Weekly

 

UNL professor granted millions for HIV vaccine research - KEYT

 

Follow 'The HInVisible Celebrity' Living with HIV for VIIV Healthcare Spain - Little Black Book - LBBonline

 

Merck's HIV combo treatment meets the bar for viral suppression in pair of phase 3 studies - Fierce Biotech

 

Considerable Scale-Up Needed to Meet 2025 HIV PrEP Goals - Physician's Weekly

 

HIV is spiking in new hot spots. Here's what's being done to control it - KANW

 

Factors associated with HIV testing among young women in Tanzania: Insights from the 2022 Tanzanian Demographic and Health Survey Using Anderson's Behavioral Model - Frontiers

 

Merck’s HIV treatment meets main goal of two late-stage studies - PharmaLive

 

What sort of monster would rape Gisèle Pelicot? The mob of HIV-riddled perverts evil husband Dominique... - The Sun

 

Coccidioidal Meningitis in a Patient With HIV - Cureus

 

Merck's HIV-1 treatment meets efficacy in Phase 3 trials - Investing.com

 

Merck's HIV treatment meets main goal of two late-stage studies By Reuters - Investing.com

 

Merck stock slips after trial data for HIV drug (MRK:NYSE) - Seeking Alpha

 

40 years later, the Pitt Men’s Study is still breaking ground in the fight against AIDS - University of Pittsburgh

 

Merck's HIV treatment meets main goal of two late-stage studies - Yahoo Finance

 

Merck's HIV treatment meets main goal of two late-stage studies - Yahoo Canada Finance

 

Merck Announces Topline Results from Pivotal Phase 3 Trials Evaluating Investigational, Once-Daily, Oral, Two-Drug, Single-Tablet Regimen of Doravirine/Islatravir (DOR/ISL) for the Treatment of Adults with Virologically Suppressed HIV-1 Infection -…

 

HIV financial data: A transformative power to ensure sustainability of the AIDS response - UNAIDS

 

‘Los Frikis’: How Cuban punk rockers injected themselves with HIV to escape political repression - NBC News

 

Merck's HIV treatment meets main goal in two late-stage studies - Reuters

 

HIV is spiking in new hot spots. Here's what's being done to control it - NPR

 

Meet 4 Inspiring Global Health Leaders Who Are Tackling HIV - Forbes

 

Development and validation of a predictive model for metabolic syndrome in a large cohort of people living with HIV - Virology Journal

 

Immune Reconstitution Inflammatory Syndrome-Induced Thrombocytopenia in a Patient With HIV and Coccidioidomycosis - Cureus